The mutational loss of CDKN2A tumor suppressor function complements KRAS activation by decreasing p16INK4a binding to CDK4/6, which leads to increased D-cyclin activation and retinoblastoma protein (Rb) phosphorylation, thus promoting PC occurrence and malignant growth [300]. The gene discussed is KRAS; the disease is pachyonychia congenita.